Molecular Residual Disease After Definitive Chemoradiotherapy in Locally Advanced Head and Neck Cancer: Clinical Value and Optimal Timing for ctDNA Assessment.
BACKGROUND: Accurate post-treatment assessment after definitive chemoradiotherapy (CRT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) remains challenging due to limitations of standard imaging. We evaluated the diagnostic performance, prognostic value and optimal timing of circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection. METHODS: Seventy-four patients with LA-HNSCC treated with definitive CRT were prospectively enrolled. Plasma samples were collected before treatment, at 8 and 12 weeks after CRT, and during follow-up. ctDNA was analysed using a plasma-only methylation-based assay. Diagnostic performance for recurrence detection and associations with progression-free survival (PFS) and overall survival (OS) were evaluated and compared with 12-week PET/CT findings. RESULTS: Baseline ctDNA was detectable in 85.1% of patients. Among post-treatment timepoints, week-12 ctDNA showed the highest diagnostic accuracy for recurrence detection, with 69% sensitivity, 100% specificity, 100% positive predictive value, and 76% negative predictive value. Detectable week-12 ctDNA was associated with shorter PFS (HR, 6.44; 95% CI, 2.73-16.74; p<0.001) and OS (HR, 7.31; 95% CI, 2.80-22.31; p<0.001 ). Longitudinal ctDNA surveillance identified additional recurrences among patients with initially undetectable week-12 ctDNA. Exploratory analyses integrating PET/CT and ctDNA identified prognostically distinct PFS groups (log-rank P=0.033), with the greatest additional prognostic stratification observed among PET partial-responders. CONCLUSIONS: Plasma-only methylation-based ctDNA provided high-specificity prognostic information after definitive CRT in LA-HNSCC, particularly at week 12 and in PET partial-responders. ctDNA may complement PET/CT for post-treatment risk stratification, but should not be used as a stand-alone test to exclude recurrence.
Authors
- Clara Alfaro‐Cervelló (ORCID: https://orcid.org/0000-0002-3737-4028)
- Blanca García-Micó (ORCID: https://orcid.org/0000-0002-9370-7966)
- Jorge Martín-Arana (ORCID: https://orcid.org/0000-0003-4554-5760)
- María Maroñas (ORCID: https://orcid.org/0000-0002-7444-4574)
- Delfina Dualde (ORCID: https://orcid.org/0000-0002-7150-8026)
- Franz Villarroel‐Espíndola (ORCID: https://orcid.org/0000-0003-0080-2444)
- Gema Bruixola (ORCID: https://orcid.org/0000-0003-3229-0770)
- Daniel G. Camblor (ORCID: https://orcid.org/0000-0002-2449-9841)
- Noelia Tarazona (ORCID: https://orcid.org/0000-0003-4888-1655)
- Francisco Gimeno-Valiente (ORCID: https://orcid.org/0000-0003-0544-9459)
- Andrès M.R. Cervantes (ORCID: https://orcid.org/0000-0003-3806-3691)
- Nuria Grimalt (ORCID: https://orcid.org/0009-0004-5815-1781)
- Belén Martínez-Castedo (ORCID: https://orcid.org/0009-0002-3629-8526)
- María Eugenia Iglesias (ORCID: https://orcid.org/0009-0003-0067-2392)
- Vicente Escorihuela García (ORCID: https://orcid.org/0009-0000-9979-7248)
- F. Martinez Martinez (ORCID: https://orcid.org/0009-0002-0760-8206)
- B. Iglesias (ORCID: https://orcid.org/0009-0001-6934-3760)
- Jim Hayes (ORCID: https://orcid.org/0000-0003-4097-8460)
- Miguel García Bartolomé (ORCID: https://orcid.org/0009-0009-2873-3517)
- Alonso García-Márquez (ORCID: https://orcid.org/0000-0003-1059-0721)
Institutions
- Massachusetts General Hospital (US)
- Hospital Clínico Universitario de Valencia (ES)
- Consorcio Hospitalario Provincial de Castellón (ES)
- Guardant (United States) (US)
- UCL Biomedical Research Centre (GB)
- INCLIVA Health Research Institute (ES)
- University College London (GB)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-1545
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundación Mutua Madrileña
- INCLIVA Instituto de Investigación Sanitaria
- Instituto de Salud Carlos III